Product name: |
Recombinant Human ACE-2 (C-mFc) |
Description: |
Recombinant Human Angiotensin-Converting Enzyme 2 is produced by our Mammalian expression system and the target gene encoding Gln18-Ser740 is expressed with a mFc tag at the C-terminus. |
Accession: |
Q9BYF1 |
Molecular weight: |
110 KDa |
Apparent molecular weight: |
110-140 KDa, reducing conditions |
Purity: |
Greater than 95% as determined by reducing SDS-PAGE. |
Endotoxin: |
Less than 0.1 ng/μg (1 EU/μg) as determined by LAL test. |
Biological activity: |
Immobilized 2019-nCoV S1 Protein (Cat#DRA35)at 10μg/ml (100μl/well) can bind Human ACE-2-mFc(Cat#C06A). The ED50 of Human ACE-2-mFc(Cat#C06A) is 45.11 ng/ml. |
Storage: |
Store at ≤-70°C, stable for 6 months after receipt.
Store at ≤-70°C, stable for 3 months under sterile conditions after opening.
Please minimize freeze-thaw cycles. |
Delivery condition: |
The product is shipped on dry ice/polar packs.
Upon receipt, store it immediately at the temperature listed below. |
Background: |
Angiotensin-Converting Enzyme 2 (ACE-2) is an integral membrane protein and a zinc metalloprotease of the ACE family, the ACE family includes somatic and germinal ACE. ACE-2 cleaves angiotensins I and II as a carboxypeptidase, ACE-2 converts angiotensin I to angiotensin 1-9, and angiotensin II to angiotensin 1-7. ACE-2 is also able to hydrolyze apelin-13 and dynorphin-13 with high efficiency. ACE-2 can be high expressed in testis, kidney and heart, in colon, small intestine and ovary at moderate levels. Captopril and lisinopril as the classical ACE inhibitor don’t inhibit ACE-2 activity. ACE-2 may play an important role in regulating the heart function. |